TL;DR
- Same primary receptor (5-HT2A). Different secondary receptor profiles. Subjective overlap is large but not complete.
- Duration is the biggest practical difference. Psilocybin: 4-6 hours. LSD: 8-12 hours. Doubles the time commitment for a session, doubles the cost of a difficult one.
- LSD is dosed in micrograms (precision dosing requires accurate blotter). Psilocybin is dosed in grams of dried mushrooms (variable potency by species and batch).
- For microdosing: LSD has cleaner sub-perceptual range. For trip therapy: psilocybin dominates the modern trial literature.
- Headspace anecdotally: psilocybin “warmer, more body, more mystical.” LSD “more cognitive, electric, longer arc.” Individual variation huge.
Side-by-side comparison
| Dimension | Psilocybin | LSD |
|---|---|---|
| Active form | Psilocin (after dephosphorylation) | LSD (parent molecule active) |
| Primary target | 5-HT2A partial agonist | 5-HT2A partial agonist + 5-HT1A, dopamine D2 affinity |
| Typical full dose | 2-5 g dried mushrooms (~10-25 mg synthetic) | 100-200 µg blotter |
| Microdose range | 0.1-0.3 g dried mushrooms (~1-3 mg synthetic) | 5-20 µg |
| Onset | 20-40 min | 30-60 min |
| Peak | 1.5-2.5 hours | 3-5 hours |
| Total duration | 4-6 hours | 8-12 hours |
| Subjective texture | Warmer, more bodily, more emotional, mystical-type more common | Sharper, more cognitive, “electric,” long arc |
| Visuals | Organic, flowing patterns, often closed-eye | Geometric, sharper edges, often open-eye |
| Tolerance | Builds within days; cross-tolerance with LSD | Builds within days; cross-tolerance with psilocybin |
| Modern clinical research | Phase 2/3 (depression, PTSD, addiction) | Microdosing trials (Maastricht); cluster headache; small therapy trials |
| Sourcing risk | Misidentification, contamination; cultivation possible | Blotter misdosing, NBOMe substitution (deadly) |
| Legality (US, May 2026) | Schedule I; Oregon & Colorado regulated programs | Schedule I; no regulated state programs |
Headspace differences (anecdotal but consistent)
Across decades of trip-report literature, two phenomenological clusters keep showing up:
Psilocybin
- Warmer, more bodily. Heart-opening, somatic awareness, emotional release more common.
- Mystical-type experience (oneness, ego dissolution, ineffability) appears more reliably than with LSD.
- Shorter arc means less wear, easier to integrate, friendlier for first-timers.
- “Nature” association in user reports — outdoor settings, plant kingdom, ancestral.
LSD
- Sharper, more cognitive. Pattern recognition, intellectual loops, conceptual play.
- Longer arc means more terrain, more turns, more capacity for difficult passages.
- Less reliable mystical-type on average, but not absent. Setting matters more.
- “Technology” association in user reports — Silicon Valley microdosing culture is largely LSD.
These are tendencies, not rules. Individual response varies. Many experienced users prefer one over the other for specific contexts.
For microdosing
Both can be microdosed. Practical differences:
- LSD has cleaner sub-perceptual range. 8-12 µg is reliably below visual threshold for most users. Volumetric dosing (dissolved in distilled water or alcohol) gives precise dose control.
- Psilocybin’s variability is real. Mushroom potency varies by species (cubensis vs azurescens), batch, and individual cap. Same gram of dried mushrooms can deliver substantially different psilocybin doses.
- LSD’s longer half-life (8-12 hours) means a morning microdose is still active mid-afternoon. Some users prefer this for a workday; others find sleep disruption if dosed late.
- Psilocybin’s shorter half-life means you can dose morning and have a clean evening.
- Sourcing: LSD blotters carry the risk of NBOMe substitution (sold as LSD, can be lethal at higher doses). Reagent test kits are non-negotiable. Mushroom misidentification is a different risk class.
For therapy
Modern clinical research has converged on psilocybin for several reasons:
- Shorter session length. 6 hours of therapist time vs 12 makes psilocybin more practical for clinical use.
- Mystical-type experience reliability. Mystical scores predict therapeutic outcome across trials. Psilocybin produces them more consistently.
- FDA pathway. COMPASS Pathways and Usona built their Phase 3 programs around synthetic psilocybin. LSD has no comparable Phase 3 program for depression/PTSD.
- Cultural baggage. LSD’s 1960s associations have made it harder to fund and gain regulatory approval, despite identical mechanism.
For cluster headaches, both work and are used by patient communities (see our cluster headaches page).
When each fits
Psilocybin fits when
- You want a shorter session (6 vs 12 hours).
- You are pursuing therapeutic protocols (depression, PTSD, cluster, addiction).
- Reliable mystical-type experience is desired.
- You can source whole mushrooms or synthetic.
- It is your first session and you want easier integration.
LSD fits when
- You want a longer arc with capacity for cognitive exploration.
- You are microdosing and want precise sub-perceptual dose control.
- You have a full day with reliable setting and sitter.
- You can source from a tested supply (Reagent kit non-negotiable).
FAQ
Are they essentially the same drug?
Mechanistically very similar (both 5-HT2A partial agonists). Subjectively similar in broad strokes (classical psychedelic experience). Practically different in duration, dosing precision, and headspace tendencies.
Which is safer?
Both have low documented physiological toxicity at recreational/therapeutic doses. Sourcing risk differs: LSD blotters can be NBOMe (deadly); mushrooms can be misidentified or contaminated. Reagent test kits address LSD risk.
Can I take both together?
Cross-tolerance means combined doses do not stack additively. Some users report “candy flipping”-like states (LSD + low-dose psilocybin). Risk profile is not characterized; we do not recommend it for therapeutic intent.
Which has more research?
Modern clinical research base is heavier for psilocybin (depression, PTSD, addiction Phase 2/3). LSD has strong cluster headache literature and the Maastricht microdosing trial.
For ADHD or focus, LSD or psilocybin?
Anecdotally LSD is more popular for daytime/workday microdosing due to its longer arc fitting an 8-hour day. Psilocybin is preferred when sleep needs to be protected. See our ADHD page.
What about mescaline, DMT, ayahuasca?
Different again. Mescaline shares the 5-HT2A pathway but with different headspace and 10-12 hour duration. DMT is short and intense. Ayahuasca is DMT with MAOI for oral activity. Each warrants its own page.
